~~SECURITIES~~UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, ~~D.C.~~DC 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934

~~Pursuant~~Date toof ~~Section 13 or 15~~Report (d)Date of ~~The~~ ~~Securities~~earliest ~~Exchange~~event ~~Act~~reported): ofJanuary 2, ~~1934~~2008 (January 1, 2008)

~~Date of Report (Date of earliest event reported): May~~AMERICAN 21MEDICAL TECHNOLOGIES, ~~2003~~INC.

American Medical Technologies, Inc.
(Exact name of Registrant as specified in its charter)
Delaware	0-19195	38-2905258
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
5555 Bear Lane Corpus Christi, TX 78405
(Address of principal executive offices)
Registrant’s telephone number, including area code: (361) 289-1145
Not Applicable
(Former name or former address, if changed since last report)

(Exact name of Registrant as specified in charter)

ITEM 2. ACQUISITION OR DISPOSITION OF ASSETS

Delaware		0-19195		38-2905258
(State or othis jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification Number)

~~On May~~5655 ~~21, 2003, the Company consummated the transactions contemplated by the~~Bear Asset Purchase Agreement that the Company entered into with Biolase Technology, Inc. on May 12, 2003, as reported in the Form 10-Q of the Company filed on May 15, 2003. The Company’s press release reporting that closing is attached as Exhibit 99.1 to this Form 8-K.Lane

~~ITEM 7. FINANCIAL STATEMENTS~~Corpus Christi, ~~PRO~~TX ~~FORMA~~78405 (Address ~~FINANCIAL~~of ~~INFORMATION~~principal ~~AND~~executive ~~EXHIBITS.~~offices)

~~(b) Pro~~Registrant’s telephone ~~Forma~~number, ~~Financial~~including ~~Information~~area code: (361) 289-1145

~~The unaudited~~Check ~~pro forma information presented below restates~~ the ~~Company’s financial~~appropriate ~~statements as of the year ended December 31, 2002 and the quarter~~box ~~ended~~below ~~March~~if ~~31, 2003, assuming~~ the ~~sale of assets to Biolase described in Item 2 of this~~ Form 8-K ~~took~~filing ~~place~~is ~~effective~~intended ~~January 1, 2002, that the purchase price of $1.825 million in cash was paid~~ to ~~Bank~~simultaneously ~~One~~satisfy ~~and that~~ the ~~307,500~~ ~~shares~~filing ofobligation ~~Biolase stock were received by the Company, as~~ of ~~that date. The unaudited pro forma information presented is for informational purposes only and is not necessarily indicative of~~ the ~~results~~Registrant ofunder ~~operations~~any ~~had the disposition~~ of the ~~assets~~following ~~occurred~~provisions (see ~~effective~~General ~~January~~Instruction 1,A.2 ~~2002~~below).

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)). o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13(e)-4(c))

~~AMERICAN~~Forward ~~MEDICAL TECHNOLOGIES~~Looking Statements

~~PRO~~This ~~FORMA~~Form 8-K ~~CONDENSED~~and ~~BALANCE~~other ~~SHEET~~reports filed by Registrant from time to time with the Securities and Exchange Commission (collectively the “Filings”) contain or may contain forward looking statements and information that are based upon beliefs of, and information currently available to, Registrant’s management as well as estimates and assumptions made by Registrant’s management. When used in the filings the words “anticipate”, “believe”, “estimate”, “expect”, “future”, “intend”, “plan” or the negative of these terms and similar expressions as they relate to Registrant or Registrant’s management identify forward looking statements. Such statements reflect the current view of Registrant with respect to future events and are subject to risks, uncertainties, assumptions and other factors (including the risks contained in the section of the Registrant’s Form 10-K entitled “Risk Factors”) relating to Registrant’s industry, Registrant’s operations and results of operations and any businesses that may be acquired by Registrant. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.

~~FOR~~Although ~~THE~~the ~~PERIOD~~Registrant ~~ENDING~~believes ~~12/31/02~~that the expectations reflected in the forward looking statements are reasonable, the Registrant cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, the Registrant does not intend to update any of the forward-looking statements to conform these statements to actual results.

~~(Unaudited)~~Item 7.01 Regulation FD Disclosure

	Historical		Division Sold		Pro Forma Adjustments			Pro Forma
			(A)		(B)
ASSETS
Current assets:
Cash	$	566,436			$	5,479	(1)	$	571,915
Accounts receivable, less allowances	472,354							472,354
Inventories	3,113,060		(1,515,862	)				1,597,198
Prepaid expenses and other current assets	197,577							197,577
Total current assets	4,349,427		(1,515,862	)	5,479			2,839,044
Non current assets:
Stock held for sale					3,693,075		(2)	3,693,075
Property and equipment, net	1,753,997		(3,586	)				1,750,411
Intangible assets, net:
Goodwill	1,971,427							1,971,427
Other	27,847		(13,924	)				13,923
NET ASSETS SOLD			1,533,372		(1,533,372		)
Total assets	$	8,102,698	—		$	2,165,182		$	10,267,880
LIABILITIES AND STOCKHOLDERS EQUITY
Current liabilities:
Accounts payable	2,714,003				(138,391		)(3)	2,575,612
Compensation and employee benefits	81,538							81,538
Accrued restructuring costs	418,335							418,335
Other accrued liabilities	318,728				(7,968		)(3)	310,760
Current notes payable	2,332,075				(1,655,656		)(3)	676,419
Total current liabilities	5,864,679		—		(1,802,015		)	4,062,664
Other non-current liabilities	4,103							4,103
Series B Preferred Stock	300,000							300,000
Total stockholders’ equity	1,933,916				3,967,197		(4)	5,901,113
Total liabilities and stockholders’ equity	$	8,102,698			$	2,165,182		$	10,267,880

On January 1, 2008, Judd Hoffman, President and Chief Executive Officer of the Registrant sent an email to the Registrant’s shareholders in which Mr. Hoffman provided a discussion of recent events related to the sale of Registrant’s securities by one of its shareholders. The email is furnished herein as Exhibit 99.1.

~~(A) Reduction~~The information in this Current Report, including the ofpresentation ~~assets~~attached hereto as aExhibit 99.1, ~~result~~is ofbeing ~~the~~furnished ~~division~~pursuant to ~~sold~~Item 7.01 and shall not be deemed “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The ~~purchaser~~information ~~did~~in the Current Report shall not ~~assume~~be incorporated by reference into any ~~liabilities~~registration statement pursuant to the Securities Act of 1933, as amended.

~~(B) (1) Remaining~~Item ~~cash~~9.01 ~~after~~Financial ~~Bank~~Statements ~~One~~and ~~debt satisfied.~~Exhibits

(2d) ~~307,500 shares received with a value of $12.01/share~~Exhibits

~~(3)~~99.1 ~~Funds~~January ~~used~~ 1, 2008 email from Mr. Hoffman to ~~eliminate~~shareholders ~~Bank~~of ~~One~~the ~~debt~~Registrant.

3SIGNATURES

~~AMERICAN~~Pursuant ~~MEDICAL~~to ~~TECHNOLOGIES~~the requirements of the Securities Exchange Act of 1934, ~~INC~~the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PRO FORMA CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS YEAR ENDED DECEMBER 31, 2002

	AMERICAN MEDICAL TECHNOLOGIES, INC.

	By:	/s/ Judd Hoffman
		Judd Hoffman,
		Chief Executive Officer and President
		Dated: January 2, 2008

~~(Unaudited)~~2

	Historical			Sold			Adjustments			Pro Forma
				(C)			(D)
REVENUES	$	8,943,076		$	(4,620,974	)				$	4,322,102
ROYALTIES	141,370			(126,683		)				14,687
	9,084,446			(4,747,657		)	—			4,336,789
COST OF SALES	8,025,136			(4,707,582		)				3,317,554
Gross profit	1,059,310			(40,075		)	—			1,019,235
COST AND EXPENSES:
Selling, general and administrative	6,772,812			(1,277,956		)	17,506		(1)	5,494,856
Research and development	595,156									595,156
Restructuring	708,242									708,242
Loss from operations	(7,016,900		)	1,237,881			(17,506		)	(5,779,019		)
Other income (expense):
Other income	17,927									17,927
Interest expense	(281,957		)	148,665					(2)	(133,292		)
Loss before income taxes	(7,280,930		)	1,386,546			(17,506		)	(5,894,384		)
Income tax (benefit) expense	(237,418		)							(237,418		)
Net Loss	$	(7,043,512	)	$	1,386,546		$	(17,506	)	$	(5,656,966	)
Net Loss per share	$	(0.98	)							$	(0.79	)
Net Loss per share assuming dilution	$	(0.98	)							$	(0.79	)

(C) Reduction of revenues and expenses as a result of the division sold. These amounts do not consider any allocation of corporate overhead to the division that was sold, and therefore, selling, general and administrative expenses do not reflect any potential reductions in corporate costs in response to the change in the Company.

(D) (1) Legal fees incurred from Bank One transactions.

(2) Reduction of interest expense as a result of Bank One loan payoff.

AMERICAN MEDICAL TECHNOLOGIES, INC.

PRO FORMA CONDENSED CONSOLIDATED BALANCE SHEET

FOR THE PERIOD ENDED 03/31/03

(Unaudited)

	Historical		Sold		Adjustments			Pro Forma
			(A)		(B)
ASSETS
Current assets:
Cash	$	390,555			$	5,479	(1)	$	396,034
Accounts receivable, less allowances	518,766							518,766
Inventories	2,503,898		(1,312,993	)				1,190,905
Prepaid expenses and other current assets	154,682							154,682
Total current assets	3,567,901		(1,312,993	)	5,479			2,260,387
Non current assets:
Stock held for sale					3,693,075		(2)	3,693,075
Property and equipment, net	1,678,497		(3,019	)				1,675,478
Intangible assets, net:
Goodwill	1,971,427							1,971,427
Other	26,212		(13,106	)				13,106
NET ASSETS SOLD			1,329,118		(1,329,118		)
Total assets	$	7,244,037	—		$	2,364,436		$	9,613,473
LIABILITIES AND STOCKHOLDERS EQUITY
Current liabilities:
Accounts payable	2,468,960				(138,391		)(3)	2,330,569
Compensation and employee benefits	83,501							83,501
Accrued restructuring costs	405,230							405,230
Other accrued liabilities	289,124				(7,968		)(3)	281,156
Current notes payable	2,332,075				(1,655,656		)(3)	676,419
Total current liabilities	5,578,890		—		(1,802,015		)	3,776,875
Other non-current liabilities	—							—
Series B Preferred Stock	300,000							300,000
Total stockholders’ equity	1,365,147				4,171,451		(4)	5,536,598
Total liabilities and stockholders’ equity	$	7,244,037	—		$	2,369,436		$	9,613,473

(A) Reduction of assets as a result of the division sold. The purchaser did not assume any liabilities.

(B) (1) Remaining cash after Bank One debt satisfied.

(2) 307,500 shares received with a value of $12.01/share

(3) Funds used to eliminate Bank One debt.

(4) Estimated gain on sale as of the pro forma balance sheet date 03/31/03.

AMERICAN MEDICAL TECHNOLOGIES, INC.

PRO FORMA CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS

PERIOD ENDED MARCH 31,2003

(Unaudited)

	Historical			Sold			Adjustments			Pro Forma
				(C)			(D)
REVENUES	$	876,895		$	(309,460	)				$	567,435
ROYALTIES	147,717			(144,623		)				3,094
	1,024,612			(454,083		)	—			570,529
COST OF SALES	891,346			(333,507		)				557,839
Gross profit	133,266			(120,576		)	—			12,690
COST AND EXPENSES:
Selling, general and administrative	658,408			(9,953		)	17,506		(1)	648,455
Research and development	77,235									77,235
Restructuring	—									—
Loss from operations	(602,377		)	(110,623		)	(17,506		)	(713,000		)
Other income (expense):
Other income	87,268									87,268
Interest expense	(51,894		)	—			34,148		(2)	(51,894		)
Loss before income taxes	(567,003		)	(110,623		)	16,642			(660,984		)
Income tax (benefit) expense	50									50
Net Loss	$	(567,053	)	$	(110,623	)	$	16,642		$	(661,034	)
Net Loss per share	$	(0.08	)							$	(0.09	)
Net Loss per share assuming dilution	$	(0.08	)							$	(0.09	)

(D) (1) Legal fees incurred from Bank One transactions.

(2) Reduction of interest expense as a result of Bank One loan payoff.

A list of Exhibits included as part of this report is set forth in the Exhibit Index which immediately precedes such Exhibit and is incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

June 5, 2003	AMERICAN MEDICAL TECHNOLOGIES, INC.
	By:	/s/	ROGER W. DARTT
		Roger W. Dartt
		Chief Executive Officer

EXHIBIT INDEX

Exhibit No.		Description
99.1		Press release regarding consummation of sale of assets to Biolase Technology, Inc.

Filing Compare · AMERICAN MEDICAL TECHNOLOGIES INC/DE